Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.
By Xiaoying Zhuang, Xiaoyu Xiang, W. Grizzle, Dongmei Sun, Shuangqin Zhang, R. Axtell, Songwen Ju, J. Mu, Lifeng Zhang, L. Steinman and 2 more. Molecular Therapy, 2011
1,271 citations recorded by the source corpus.
In this study, exosomes used to encapsulate curcumin (Exo-cur) or a signal transducer and activator of transcription 3 (Stat3) inhibitor, i.e., JSI124 (Exo-JSI124) were delivered noninvasively to microglia cells via an intranasal route. The results generated from three inflammation-mediated disease models, i.e., a lipopolysaccharide (LPS)-induced brain inflammation model, experimental autoimmune encephalitis and a GL26 brain tumor model, showed that mice treated intranasally with Exo-cur or Exo-JSI124 are protected from LPS-induced brain inflammation, the progression of myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune encephalomyelitis (EAE), and had significantly delayed brain tumor growth in the GL26 tumor model. Intranasal administration of Exo-cur or Exo-JSI124 led to rapid delivery of exosome encapsulated drug to the brain that was selectively taken up by microglial cells, and subsequently induced apoptosis of microglial cells. Our results demonstrate that this strategy may provide a noninvasive and novel therapeutic approach for treating brain inflammatory-related diseases.
Subfields: Molecular Biology, Molecular Medicine, Neurology
View Paper: https://www.semanticscholar.org/paper/3a0832bef5ef8d33852b4d9178d301f5e694feb3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Molecular Medicine
Citations in the corpus
- Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review (2013, positive): “Additionally, Zhuang and colleagues utilized an exosome-encapsulated curcumin formulation to demonstrate superior activity against brain inflammatory diseases [224].”
- Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “Upon administration to the brain through intranasal routes, curcumin-loaded EVs protected mice from LPS-induced brain inflammation and from the progression of myelin oligodendrocyte glycoprotein peptide induced experimental autoimmune encephalomyelitis (245).”
- Standardization of sample collection, isolation and analysis methods in extracellular vesicle research (2013, positive): “Understanding nasal EV is of particular importance since therapeutic vesicles could be transported to the brain through the olfactory system (181).”
- Using exosomes, naturally-equipped nanocarriers, for drug delivery (2015, background): “Thus, low molecular antioxidant, curcumin [89,90], anticancer agents, Doxorubicin (Dox) [92,93] and Paclitaxel (PTX) [94], and a model drug Rhoda-mine 123 [94] were loaded into exosomes or exosome-like vesicles by incubation at room temperature (RT).”
- Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio (2015, methodology): “A hydrophobic polyphenol curcumin was loaded into exosomes purified from an EL-4 mouse lymphoma cell line by simple incubation (11).”
- Brief update on endocytosis of nanomedicines (2019, background): “Small molecules, such as curcumin [185], doxorubicin [177] and paclitaxel [178,184], were encapsulated in exosomes by co-incubation, mild sonication, or extrusion (Fig.”
- Exosome Theranostics: Biology and Translational Medicine (2018, background): “They are membrane-permeable and can also cross the blood-brain barrier [168].”